The present invention is directed to the identification and use of agents, particularly peptides and monoclonal antibodies that disrupt the interaction between Collagen XIII and α1β1 integrin.Linvention concerne lidentification et lutilisation dagents, notamment des peptides et des anticorps monoclonaux, qui disloquent linteraction entre le collagène XIII et lintégrine ?1?1.